Research programme: diabetes therapeutics - Theracos

Drug Profile

Research programme: diabetes therapeutics - Theracos

Alternative Names: CLX-0100; CLX-0940; THR-0100; THR-0940

Latest Information Update: 09 Nov 2009

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Calyx Therapeutics (CEASED)
  • Developer Theracos
  • Class Peptides; Stilbenes
  • Mechanism of Action Peroxisome proliferator-activated receptor alpha agonists; Peroxisome proliferator-activated receptor gamma agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Preclinical Type 2 diabetes mellitus

Most Recent Events

  • 09 Nov 2009 Preclinical development for type-2 diabetes mellitus is ongoing
  • 31 May 2003 Theracos acquires assets from Calyx Therapeutics
  • 29 Jan 2003 CLX 0100 is available for licensing (http://www.calyxti.com)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top